Gemmer Asset Management LLC Nektar Therapeutics Transaction History

Gemmer Asset Management LLC

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 20, 2022	SELL	$4.16 - $13.72 $1,510 - $4,980	-363 Closed	0 $0
Q4 2021 Jan 21, 2022	SELL	$10.83 - $18.41 $1,451 - $2,466	-134 Reduced 26.96%	363 $5,000
Q2 2021 Jul 23, 2021	BUY	$16.52 - $20.4 $3,304 - $4,079	200 Added 67.34%	497 $9,000
Q1 2021 Apr 20, 2021	BUY	$16.56 - $25.46 $380 - $585	23 Added 8.39%	297 $6,000
Q4 2020 Jan 28, 2021	BUY	$15.77 - $19.03 $205 - $247	13 Added 4.98%	274 $5,000
Q3 2020 Oct 21, 2020	BUY	$16.59 - $24.79 $232 - $347	14 Added 5.67%	261 $4,000
Q2 2020 Jul 31, 2020	SELL	$16.86 - $23.44 $1,567 - $2,179	-93 Reduced 27.35%	247 $6,000
Q1 2020 May 01, 2020	SELL	$14.47 - $27.96 $17,508 - $33,831	-1,210 Reduced 78.06%	340 $6,000
Q4 2019 Jan 17, 2020	SELL	$15.87 - $23.12 $968 - $1,410	-61 Reduced 3.79%	1,550 $33,000
Q3 2019 Oct 11, 2019	BUY	$16.91 - $36.27 $3,737 - $8,015	221 Added 15.9%	1,611 $29,000
Q2 2019 Jul 18, 2019	BUY	$31.0 - $36.3 $35,619 - $41,708	1,149 Added 476.76%	1,390 $49,000
Q4 2018 Jan 18, 2019	SELL	$30.43 - $56.65 $2,799 - $5,211	-92 Reduced 27.63%	241 $8,000
Q3 2018 Oct 12, 2018	SELL	$46.46 - $68.49 $7,340 - $10,821	-158 Reduced 32.18%	333 $20,000
Q2 2018 Jul 18, 2018	SELL	$46.25 - $104.45 $555 - $1,253	-12 Reduced 2.39%	491 $24,000
Q1 2018 May 11, 2018	BUY	$57.4 - $108.44 $688 - $1,301	12 Added 2.44%	503 $53,000
Q4 2017 Jan 16, 2018	BUY	$23.02 - $60.5 $598 - $1,573	26 Added 5.59%	491 $29,000
Q3 2017 Oct 12, 2017	BUY	$17.79 - $24.0 $8,272 - $11,160	465	465 $11,000

140

135M

32.8K

55.5K

Ticker NKTR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,404,992
Market Cap $244M
Description
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...

Get notified when there are updates to the investment portfolio of Gemmer Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Gemmer Asset Management LLC with notifications on news.